Participated · Equity · May 2022

Germitec develops and manufactures UV-C high-level disinfection systems aimed primarily at disinfecting ultrasound probes used in fertility (IVF), gynecology, cardiology and ENT. Its products are available in 40 countries and protect approximately 2.2 million patients worldwide each year. The company received an FDA De Novo granted in August 2024 and cites a U.S. market opportunity of 60,000 units. Germitec says it is positioned to double its revenue every year with profitability on the horizon. Proceeds from the recent financing will be used to scale U.S. operations, accelerate commercial adoption and invest in R&D to expand its product portfolio. Combined with prior financing from the European Investment Bank in 2023, the company expects sustained growth over the next two years. GERMITEC designs and commercializes automated UV‑C high‑level disinfection (HLD) systems for external, vaginal, rectal and transesophageal ultrasound probes, including products Hypernova Chronos, Antigermix AE1 and the PROUV traceability system. The company positions its chemical‑free devices as faster, simpler and cleaner replacements for wipes, soaking and hydrogen peroxide workflows and notes approvals in over 35 countries. GERMITEC says its UV‑C HLD address Healthcare‑Acquired Infections and aims to make UV‑C HLD a standard of care; its market opportunity is cited at about €245M. The company has 15 years of product development experience and won the 2020 Prix Galien for Best Medical Device. With the new capital and management team, GERMITEC plans European and international commercial expansion and is preparing a U.S. go‑to‑market strategy following planned FDA clearance. The financing and leadership changes are framed as steps to transform GERMITEC into a high‑growth commercial company and to continue product innovation and operational structuring.

Led · Equity · Apr 2020

CyberMDX builds a cyber‑intelligence platform that inventories and manages hospitals' network‑connected assets and devices and monitors threats in real time. The company focuses on securing medical devices and improving hospital network security. Its research arm has discovered vulnerabilities in widely used medical devices and protocols, prompting a Homeland Security alert. CyberMDX was founded four years ago and is based in New York. The company raised $20 million in its latest financing and said it will use the proceeds to roll out its platform across new geographies and markets. Management framed the timing as important given the strain hospitals face from the COVID‑19 pandemic and said the platform can help support the healthcare community. CyberMDX provides a non-intrusive cybersecurity platform that delivers zero-touch visibility, risk management, and threat prevention and detection for medical devices and clinical networks (IoMT). The company focuses on protecting critical hospital assets such as MRIs, patient monitors and infusion pumps that often run legacy, unpatched systems. Its multidisciplinary team includes veterans of Israeli intelligence cyber units, medical device experts, and AI academic leaders; founders named in the article are Amir Magner and Moti Shniberg. CyberMDX emphasizes a scalable, easy-to-deploy solution to ensure operational continuity, patient safety and data protection. The company announced a $10 million Series A led by Pitango Venture Capital with participation from OurCrowd Qure and plans to expand its medical cybersecurity offering to hospitals worldwide.

Participated · Series C · Sep 2015

Biom'Up develops a new generation hemostatic product, HEMOBLAST TM, and markets proprietary collagen-based products including COVA TM, COVAMESH TM and MATRITM BONE. The company focuses on absorbable medical devices for use in biosurgery. Management is led by CEO Étienne Binant. Biom'Up reported turnover of more than €3m in 2014 and expected over 30% sales growth for its existing product portfolio in 2015. The company plans to use new funds to further develop HEMOBLAST TM, specifically to support its clinical study activities in Europe and North America. Operations are based in Saint-Priest, France. Biom'Up designs, develops and manufactures re-absorbable medical implants for a range of surgical applications from nerve regeneration to cardio-thoracic surgery. Its marketed products include COVA, a membrane for prevention of adhesions and controlled healing available in Europe and the US, and MATRI BONE, a bone regeneration matrix sold in Europe. The company employs 27 people, including eight engineers and three doctors. Biom'Up plans to use new funding to strengthen its sales team to accelerate domestic and export roll-out and to finance a phase III clinical trial in Europe and the US for a new product range targeting major surgery and regenerative medicine markets. It has initiated a US development strategy by filing initial 510(k) applications with the FDA and establishing a multidisciplinary scientific advisory board of opinion leaders in France and the US. Founded in 2005 and based in Lyon, France, Biom'Up is focused on advancing its clinical pipeline and commercial expansion.

Participated · Equity · Sep 2014

Amolyt Pharma (referred to in the article as Alize Pharma) focuses on creating innovative peptide and protein drugs targeting metabolic disorders and oncology indications. Its lead asset, AZP-531, is an eight-amino-acid unacylated ghrelin analog being advanced for Type II diabetes and Prader-Willi syndrome; the company expects to start Phase I trials in healthy volunteers in 2013, followed by Phase Ib/II studies in patients. A second program, ASPAREC, is a PEGylated recombinant L-asparaginase for acute lymphoblastic leukemia that is already in Phase I and partnered with EUSA Pharma. The firm controls five patent families covering 34 patents and applications around UAG, its analogs, and related uses. Founded in 2007, the company pursues a strategy of bringing assets to early clinical proof-of-concept before licensing to larger pharmaceutical partners. Including the current round, Amolyt/Alize has raised a total of €8.3 million from private and institutional backers to fund its R&D milestones and clinical progression.

Participated · Series D · Apr 2014

Voluntis develops digital therapeutics using its Theraxium technology platform. The company is focused on tools to support patients treated for cancer and is exploring applications in neurology. Voluntis and Eisai will collaborate to design and develop innovative digital therapeutics for oncology patients using Theraxium. Eisai made a strategic investment in Voluntis as part of the collaboration. The partners plan to explore additional opportunities to develop, evaluate and commercialize Theraxium-based digital therapeutics in neurology. The article presents this activity as part of Voluntis expanding its global pharma collaborations. Voluntis develops proprietary companion software dedicated to managing chronic conditions, with a focus on diabetes, anticoagulation and hemophilia. Its Voluntis Insulin Therapy Manager (VITM) is designed to support patients across the insulin pathway. The company also provides partners with development and regulatory capabilities to build digital solutions on its core system architecture. Voluntis plans to use the new funding to accelerate development of its diabetes management solution, advance programs in other chronic diseases, and ramp up US operations. The company has offices in Paris and Boston and was founded in 2001 by CEO Pierre Leurent. The Series D proceeds will support product development and geographic expansion in the US.